News Related to Samsung Epis Holdings

Related coverage linked through entity extraction aliases.

Samsung Bioepis advances first new drug SBE303 into global Phase 1 trial

Apr 14, 2026

Samsung Bioepis plans to start a global Phase 1 trial of SBE303, its first independently developed new drug candidate targeting Nectin-4. Preclinical data showed tolerability up to 40 mg/kg in monkeys.

Samsung Bioepis settles Eylea biosimilar patent dispute, secures U.S. launch in 2027

Mar 02, 2026

Samsung Bioepis reached settlement agreements with Regeneron and Bayer for its aflibercept biosimilar OPUVIZ, enabling U.S. launch in January 2027 and staged international rollout beginning early 2026.